thestudygroupwassignificantlyhigherthanthat(16.7%)ofthewomeninthecontrolgroup(P<0.05).ThelevelsofserumsCD14andTLR2ofthewomenwithpoorpregnancyoutcomesinthestudygroupweresignificantlyhigherthanthoseofthewomenwithnormalpregnancyoutcomes(P<0.05).Multivariatelogisticregressionanalysisshowedbenefit or do not, have next to being predictive also prognostic value, are continuous instead of categorical, and are therefore diwdtcult to use in daily practice. Currently, PD-L1 by immunohistochemical staining is the only approved biomarker to select metastatic non-small cell lung cancer patients for single agent pembrolizumab treatment. This may be extended with